Thus, acquired resistance in tumours bearing clonal CREBBP/EP300 alterations may be driven by genome duplication, which could potentiate the oncogenic functions of CREBBP/EP300 already present in the founder clone33,34. This evidence concerns the gene CREBBP and neoplasm.